Jazz Pharma Plc (NQ: JAZZ )
143.35 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Mar 27, 2023 Add to My Watchlist
All News about Jazz Pharma Plc
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
March 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
This Company's 18-Month CBD Stability Achievement Could Hint Towards Expansion Goals As It Plans To Release First Commercial UST System In 2022
February 10, 2022
Photo by Kindel Media from Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Jazz Pharmaceuticals Begins Enrollment For Clinical Trial To Evaluate JZP150 For Adults With PTSD
December 30, 2021
Biopharmaceutical company Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced Thursday that it has enrolled the first patient in its Phase 2 clinical trial evaluating the safety and...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following